Pathway‐structured predictive modeling for multi‐level drug response in multiple myeloma
暂无分享,去创建一个
Nengjun Yi | Xinyan Zhang | Hongxia Xu | Zixuan Yi | Bingzong Li | Huiying Han | Sha Song | Yating Hong | Wenzhuo Zhuang | N. Yi | Xinyan Zhang | Sha Song | Huiying Han | Hongxia Xu | Wenzhuo Zhuang | Bingzong Li | Yating Hong | Zixuan Yi
[1] M van Duin,et al. Pharmacogenomics and chemical library screens reveal a novel SCFSKP2 inhibitor that overcomes Bortezomib resistance in multiple myeloma , 2016, Leukemia.
[2] C. O’Brien. Statistical Learning with Sparsity: The Lasso and Generalizations , 2016 .
[3] Justin Zobel,et al. Prediction of breast cancer prognosis using gene set statistics provides signature stability and biological context , 2010, BMC Bioinformatics.
[4] R. Tibshirani,et al. Statistical Applications in Genetics and Molecular Biology Pre-validation and inference in microarrays , 2011 .
[5] Carlos Caldas,et al. A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the Proliferation, Immune response and RNA splicing modules in breast cancer , 2008, Breast Cancer Research.
[6] Gastone Castellani,et al. The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD) , 2015, Oncotarget.
[7] Hong Chang,et al. Multiple myeloma acquires resistance to EGFR inhibitor via induction of pentose phosphate pathway , 2015, Scientific Reports.
[8] Anthony Boral,et al. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. , 2006, Blood.
[9] Lana X. Garmire,et al. A Novel Model to Combine Clinical and Pathway-Based Transcriptomic Information for the Prognosis Prediction of Breast Cancer , 2014, PLoS Comput. Biol..
[10] N. Cox,et al. Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines , 2014, Genome Biology.
[11] S. Rajkumar,et al. Treatment of multiple myeloma , 2011, Nature Reviews Clinical Oncology.
[12] S. Jagannath,et al. CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION , 1998, British journal of haematology.
[13] S Vincent Rajkumar,et al. Multiple myeloma. , 2009, Current problems in cancer.
[14] N. Normanno,et al. Epidermal growth factor receptor (EGFR) signaling in cancer. , 2006, Gene.
[15] Xinyan Zhang,et al. Pathway-Structured Predictive Model for Cancer Survival Prediction: A Two-Stage Approach , 2016 .
[16] M van Duin,et al. RPL5 on 1p22.1 is recurrently deleted in multiple myeloma and its expression is linked to bortezomib response , 2016, Leukemia.
[17] Yuqiu Jiang,et al. Personalized medicine in oncology: tailoring the right drug to the right patient. , 2010, Biomarkers in medicine.
[18] 中尾 光輝,et al. KEGG(Kyoto Encyclopedia of Genes and Genomes)〔和文〕 (特集 ゲノム医学の現在と未来--基礎と臨床) -- (データベース) , 2000 .
[19] G. Roodman,et al. Chemokines in multiple myeloma. , 2006, Experimental hematology.
[20] Brad T. Sherman,et al. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists , 2008, Nucleic acids research.
[21] David B. Dunson,et al. Bayesian Data Analysis , 2010 .
[22] Trevor Hastie,et al. Regularization Paths for Generalized Linear Models via Coordinate Descent. , 2010, Journal of statistical software.
[23] D. Dingli,et al. Improved survival in multiple myeloma and the impact of novel therapies. , 2008, Blood.
[24] William N. Venables,et al. Modern Applied Statistics with S , 2010 .
[25] Brad T. Sherman,et al. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.
[26] Christina Kendziorski,et al. Pathway index models for construction of patient‐specific risk profiles , 2013, Statistics in medicine.
[27] A. Wells,et al. DU145 human prostate carcinoma invasiveness is modulated by urokinase receptor (uPAR) downstream of epidermal growth factor receptor (EGFR) signaling. , 2004, Experimental cell research.
[28] Andrei Zinovyev,et al. Computational Systems Biology of Cancer , 2020 .
[29] Alex Arenas,et al. Improved prognostic classification of breast cancer defined by antagonistic activation patterns of immune response pathway modules , 2010, BMC Cancer.
[30] Y. Kang,et al. Epidermal growth factor signalling and bone metastasis , 2009, British Journal of Cancer.
[31] P. Warner. Ordinal logistic regression , 2008, Journal of Family Planning and Reproductive Health Care.
[32] Trevor Hastie,et al. Regularization Paths for Cox's Proportional Hazards Model via Coordinate Descent. , 2011, Journal of statistical software.
[33] K. Podar,et al. Inhibition of VEGF Signaling Pathways in Multiple Myeloma and Other Malignancies , 2007, Cell cycle.
[34] Doheon Lee,et al. Inferring Pathway Activity toward Precise Disease Classification , 2008, PLoS Comput. Biol..
[35] Andrew Gelman,et al. Data Analysis Using Regression and Multilevel/Hierarchical Models , 2006 .
[36] R. Fonseca,et al. Trends in overall survival and costs of multiple myeloma, 2000–2014 , 2016, Leukemia.
[37] M. G. Pittau,et al. A weakly informative default prior distribution for logistic and other regression models , 2008, 0901.4011.